Scientific Data Images
for Human Phospho-STAT3 (Y705) Antibody
Detection of Human Phospho-STAT3 (Y705) by Western Blot.
Western blot shows lysates of Daudi human Burkitt's lymphoma cell line and HepG2 human hepatocellular carcinoma cell line untreated (-) or treated (+) with 500 U/mL Recombinant Human IFN-aA (Catalog # 11100-1) for 20 minutes or 50 µg/mL Recombinant Human IL-22 (Catalog # 782-IL) for 15 minutes. PVDF membrane was probed with 0.5 µg/mL of Rabbit Anti-Human Phospho-STAT3 (Y705) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4607) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for STAT3 at approximately 95 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Detection of Phospho-STAT3 (Y705) in IFN-alpha-treated Human Daudi Cell Line by Flow Cytometry.
Daudi human Burkitt's lymphoma cell line was unstimulated (light orange filled histogram) or treated with 500 U/mL rhIFN-alpha for 20 minutes (dark orange filled histogram) was stained with Human Phospho-STAT3 (Y705) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4607) or control antibody (Catalog # AB-105-C, open histogram), followed by Phycoerythrin-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # F0110). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with methanol.
STAT3 in Daudi Human Burkitt's Lymphoma Cells.
Phospho-STAT3 was detected in immersion fixed IFN-alpha treated Daudi human Burkitt's lymphoma cell line using 10 µg/mL Human Phospho-STAT3 (Y705) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4607) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Detection of Human STAT3 by Simple WesternTM.
Simple Western shows lysates of Daudi human Burkitt's lymphoma cell line untreated (-) or treated (+) with 50 µg/mL Recombinant Human IL-22 (Catalog # 782-IL) for 15 minutes, loaded at 0.2 mg/ml. A specific band was detected for STAT3 at approximately 91 kDa (as indicated) using 10 µg/mL of Rabbit Anti-Human Phospho-STAT3 (Y705) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4607). This experiment was conducted under reducing conditions and using the 12-230kDa separation system.
Detection of Human STAT3 by Western Blot
IL-22BPi1 does not interact with IL-22 or IL-22BPi2. (A) A549 cells were exposed for 30 minutes to dilutions of IL-22-containing culture medium (CM) previously produced by IL22-transfected HEK293 cells. A549 cell lysates (CL) were immunoblotted for pSTAT3 and tubulin as loading control. The relative densitometry of pSTAT3 normalized to that of tubulin is also represented. (B) A549 cells were treated with the optimum IL-22 dilution from A (1/512) for different periods of time, lysed and immunoblotted for pSTAT3. An unspecific protein band (u.p.) was used as loading control. (C) IL-22BP concentration in conditioned medium (CM) of transfected HEK293 cells was measured by ELISA, and the indicated amounts in nanograms (ng) of IL-22BPi1 or IL-22BPi2 were pre-incubated for 1 h at 37°C with the selected IL-22 concentration from (A). A549 were exposed to the pre-incubated combinations for 20 min. An excess of IL-22BPi2 was used as phosphorylation blocking control (lane 3). Cells were lysed and immunoblotted for pSTAT3 and actin as loading control. (D) HeLa cells were co-transfected with the indicated expression plasmids, 24 h later cells were lysed and the CM was subjected to acetone precipitation (AP), and proteins were immunoblotted for FLAG. Intracellular IL-22BPi1 is indicated with dark purple arrows, intracellular and secreted IL-22BPi2 is indicated with green arrows, and co-expressed IL-22 and IL-17 are also indicated. (E) Conditioned media (CM) from 3 independent experiments, in which expression vectors for the three IL-22BP isoforms were individually transfected into HEK293 cells together with either IL-17 or IL-22 expression vectors or an empty vector control (EV), were analyzed 24 h after transfection by ELISA for IL-22BP (mean ± SEM; n = 3; **p < 0.01 by unpaired t-test). (F) IL-22BPi1 does not interact with IL-22BPi2. IL-22BPi1-MF expression plasmid containing Myc and FLAG tags was co-transfected with an inducible pTRE3G-based vector expressing IL-22BPi2 with only a FLAG tag. After 24 h, cells were induced for IL-22BPi2 production by adding Tet-Express activator to the medium for a further 24 h. Cells were lysed and immunoprecipitated with anti-Myc agarose, the flow-through fractions were then further subjected to FLAG immunoprecipitation. CL and eluted fractions were immunoblotted for FLAG. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30619294), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human STAT3 by Western Blot
IL-22BPi1 does not interact with IL-22 or IL-22BPi2. (A) A549 cells were exposed for 30 minutes to dilutions of IL-22-containing culture medium (CM) previously produced by IL22-transfected HEK293 cells. A549 cell lysates (CL) were immunoblotted for pSTAT3 and tubulin as loading control. The relative densitometry of pSTAT3 normalized to that of tubulin is also represented. (B) A549 cells were treated with the optimum IL-22 dilution from A (1/512) for different periods of time, lysed and immunoblotted for pSTAT3. An unspecific protein band (u.p.) was used as loading control. (C) IL-22BP concentration in conditioned medium (CM) of transfected HEK293 cells was measured by ELISA, and the indicated amounts in nanograms (ng) of IL-22BPi1 or IL-22BPi2 were pre-incubated for 1 h at 37°C with the selected IL-22 concentration from (A). A549 were exposed to the pre-incubated combinations for 20 min. An excess of IL-22BPi2 was used as phosphorylation blocking control (lane 3). Cells were lysed and immunoblotted for pSTAT3 and actin as loading control. (D) HeLa cells were co-transfected with the indicated expression plasmids, 24 h later cells were lysed and the CM was subjected to acetone precipitation (AP), and proteins were immunoblotted for FLAG. Intracellular IL-22BPi1 is indicated with dark purple arrows, intracellular and secreted IL-22BPi2 is indicated with green arrows, and co-expressed IL-22 and IL-17 are also indicated. (E) Conditioned media (CM) from 3 independent experiments, in which expression vectors for the three IL-22BP isoforms were individually transfected into HEK293 cells together with either IL-17 or IL-22 expression vectors or an empty vector control (EV), were analyzed 24 h after transfection by ELISA for IL-22BP (mean ± SEM; n = 3; **p < 0.01 by unpaired t-test). (F) IL-22BPi1 does not interact with IL-22BPi2. IL-22BPi1-MF expression plasmid containing Myc and FLAG tags was co-transfected with an inducible pTRE3G-based vector expressing IL-22BPi2 with only a FLAG tag. After 24 h, cells were induced for IL-22BPi2 production by adding Tet-Express activator to the medium for a further 24 h. Cells were lysed and immunoprecipitated with anti-Myc agarose, the flow-through fractions were then further subjected to FLAG immunoprecipitation. CL and eluted fractions were immunoblotted for FLAG. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30619294), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human STAT3 by Western Blot
IL-22BPi1 does not interact with IL-22 or IL-22BPi2. (A) A549 cells were exposed for 30 minutes to dilutions of IL-22-containing culture medium (CM) previously produced by IL22-transfected HEK293 cells. A549 cell lysates (CL) were immunoblotted for pSTAT3 and tubulin as loading control. The relative densitometry of pSTAT3 normalized to that of tubulin is also represented. (B) A549 cells were treated with the optimum IL-22 dilution from A (1/512) for different periods of time, lysed and immunoblotted for pSTAT3. An unspecific protein band (u.p.) was used as loading control. (C) IL-22BP concentration in conditioned medium (CM) of transfected HEK293 cells was measured by ELISA, and the indicated amounts in nanograms (ng) of IL-22BPi1 or IL-22BPi2 were pre-incubated for 1 h at 37°C with the selected IL-22 concentration from (A). A549 were exposed to the pre-incubated combinations for 20 min. An excess of IL-22BPi2 was used as phosphorylation blocking control (lane 3). Cells were lysed and immunoblotted for pSTAT3 and actin as loading control. (D) HeLa cells were co-transfected with the indicated expression plasmids, 24 h later cells were lysed and the CM was subjected to acetone precipitation (AP), and proteins were immunoblotted for FLAG. Intracellular IL-22BPi1 is indicated with dark purple arrows, intracellular and secreted IL-22BPi2 is indicated with green arrows, and co-expressed IL-22 and IL-17 are also indicated. (E) Conditioned media (CM) from 3 independent experiments, in which expression vectors for the three IL-22BP isoforms were individually transfected into HEK293 cells together with either IL-17 or IL-22 expression vectors or an empty vector control (EV), were analyzed 24 h after transfection by ELISA for IL-22BP (mean ± SEM; n = 3; **p < 0.01 by unpaired t-test). (F) IL-22BPi1 does not interact with IL-22BPi2. IL-22BPi1-MF expression plasmid containing Myc and FLAG tags was co-transfected with an inducible pTRE3G-based vector expressing IL-22BPi2 with only a FLAG tag. After 24 h, cells were induced for IL-22BPi2 production by adding Tet-Express activator to the medium for a further 24 h. Cells were lysed and immunoprecipitated with anti-Myc agarose, the flow-through fractions were then further subjected to FLAG immunoprecipitation. CL and eluted fractions were immunoblotted for FLAG. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30619294), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human Human Phospho-STAT3 (Y705) Antibody by Western Blot
N-EV and H-EV treatment promote macrophage M2 polarization by delivering miR-21-5p that targets PTEN. a, western blot analysis of PTEN protein expression level in induced macrophages. H/i-miR-EV, monocytes were induced with the presence of EV secreted by miR-21-5p-inhibited, hypoxia pre-challenged MSCs; H-EV + i-miR, monocytes were transfected with miR-21-5p inhibitor-expressing vector before induction with the presence of H-EV. Macrophages induced without MSC-EV were used as negative control (NC). b, c, flow cytometry determining the percentage of CD163+CD206+ cells among total CD68+ cells after induction. N-EV + O/E PTEN or H-EV + O/E PTEN, monocytes were transfected with PTEN overexpressing vector before N-EV or H-EV treatment, respectively. d–f, western blot detecting Akt and STAT3 protein expression as well as their activating phosphorylation (p-Ser473 for Akt and p-tyr705 for STAT3) in macrophages after induction. g–i, ELISA evaluating IL-10, TGF-beta and VEGF-alpha in macrophage culture medium after induction. Macrophages induced with the presence of N-EV were used as negative control in b–i. Tukey’s test was used for statistical analysis. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30736829), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Phospho-STAT3 (Y705) by Flow Cytometry
Interleukin 6 (IL-6) and STAT3 expression in BC cells. (A) IL-6 levels were measured by ELISA assay in supernatants of MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells. IL-6 mRNA relative levels of MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells were also recorded. (B) Expression of activated STAT3 (STAT3pY705) in MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells was analyzed by flow cytometry (gray peak). As the negative control, the secondary antibody alone was used (white peak). (C) STAT3 mRNA relative levels of MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells. (D) STAT3 phosphorylation levels (STAT3pY705-dark gray peak with tracing line) were analyzed in MDA-MB-231 and MDA-MB-157 cells treated with Tocilizumab (TCZ), recombinant IL-6 (rIL-6) and STAT3 inhibitor, STATTIC (STC). As the negative control, the secondary antibody alone was used (white peak). * p < 0.05; ** p < 0.001. Three independent experiments were performed. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35626741), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Phospho-STAT3 (Y705) by Flow Cytometry
Interleukin 6 (IL-6) and STAT3 expression in BC cells. (A) IL-6 levels were measured by ELISA assay in supernatants of MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells. IL-6 mRNA relative levels of MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells were also recorded. (B) Expression of activated STAT3 (STAT3pY705) in MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells was analyzed by flow cytometry (gray peak). As the negative control, the secondary antibody alone was used (white peak). (C) STAT3 mRNA relative levels of MCF-10, MCF-7, MDA-MB-231, BT-549, MDA-MB-157 and MDA-MB-453 cells. (D) STAT3 phosphorylation levels (STAT3pY705-dark gray peak with tracing line) were analyzed in MDA-MB-231 and MDA-MB-157 cells treated with Tocilizumab (TCZ), recombinant IL-6 (rIL-6) and STAT3 inhibitor, STATTIC (STC). As the negative control, the secondary antibody alone was used (white peak). * p < 0.05; ** p < 0.001. Three independent experiments were performed. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35626741), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Phospho-STAT3 (Y705) by Western Blot
Aspirin modulated the JAK/p-STAT3 signaling pathway in atypical hyperplastic intestinal mucosal cells of UC mice (n = 4 for each group). (A) Western blotting images for JAK/p-STAT3 signaling pathway-associated molecules expression. (B) Statistical analysis and comparison for p-STAT3 expression. (C) Statistical analysis and comparison for STAT3 expression. (D) Statistical analysis and comparison for cyclin D1 expression. (E) Statistical analysis and comparison for SOCS3 expression. *P <.05 versus control group. uc model jak janus kinase ulcerative colitis p-stat3 phosphorylated-stat3 stat3 signal transducer and activator of transcription socs3 suppressor cytokine signaling image collected cropped by citeab from the following open publication licensed under a cc-by license. not internally tested r systems.>
Detection of Phospho-STAT3 (Y705) by Western Blot
Aspirin modulated the JAK/p-STAT3 signaling pathway in atypical hyperplastic intestinal mucosal cells of UC mice (n = 4 for each group). (A) Western blotting images for JAK/p-STAT3 signaling pathway-associated molecules expression. (B) Statistical analysis and comparison for p-STAT3 expression. (C) Statistical analysis and comparison for STAT3 expression. (D) Statistical analysis and comparison for cyclin D1 expression. (E) Statistical analysis and comparison for SOCS3 expression. *P <.05 versus control group. uc model jak janus kinase ulcerative colitis p-stat3 phosphorylated-stat3 stat3 signal transducer and activator of transcription socs3 suppressor cytokine signaling image collected cropped by citeab from the following open publication licensed under a cc-by license. not internally tested r systems.>
Applications
for Human Phospho-STAT3 (Y705) Antibody
Application
Recommended Usage
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Flow Cytometry
0.25 µg/106 cells
Sample: Daudi human Burkitt's lymphoma cell line treated with IFN-alpha, fixed with paraformaldehyde and permeabilized with methanol
Immunocytochemistry
5-15 µg/mL
Sample: Immersion fixed IFN-alpha treated Daudi human Burkitt's lymphoma cell line
Simple Western
10 µg/mL
Sample: Daudi human Burkitt's lymphoma cell line untreated (-) or treated (+) with 50 µg/mL Recombinant Human IL-22 (Catalog # 782-IL) for 15 minutes
Western Blot
0.25-0.5 µg/mL
Sample: Daudi human Burkitt's lymphoma cell line treated with Recombinant Human IFN‑ alphaA (Catalog # 11100-1) and HepG2 human hepatocellular carcinoma cell line treated with Recombinant Human IL‑22 (Catalog # 782-IL)
Reviewed Applications
Read 3 reviews rated 4.7 using AF4607 in the following applications:
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: STAT3
Signal Transducer and Activator of Transcription (STAT) proteins are transcription factors activated in response to cytokine, growth factor, or hormone receptor signaling. Janus kinases (JAKs) phosphorylate STAT proteins and induce dimerization. Homo- or heterodimers translocate to the nucleus where they bind to DNA and activate transcription.
Long Name
Signal Transducer and Activator of Transcription 3
Alternate Names
Acute-phase response factor, APRFMGC16063, DNA-binding protein APRF, FLJ20882, HIES, signal transducer and activator of transcription 3, signal transducer and activator of transcription 3 (acute-phase responsefactor)
Bio-Techne uses cookies to provide you with a great website experience. By continuing to use this website you acknowledge this and agree to our cookie policy. Learn more.